Who is sponsoring NCT04027972?

NCT04027972 is sponsored by James J. Peters Veterans Affairs Medical Center.

What drugs are being tested in NCT04027972?

Interventions in NCT04027972: Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics.

What condition does NCT04027972 study?

NCT04027972 studies Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel.

Is NCT04027972 still recruiting?

NCT04027972 is currently completed. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT04027972

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics of Neostigmine and Glycopyrrolate

Completed EARLY_PHASE1 Last updated 17 September 2025

What this trial tests

EARLY_PHASE1 trial testing Combination of Neostigmine and Glycopyrrolate in Spinal Cord Injuries in 13 participants. Completed in 20 December 2022.

Timeline

9 March 2020

Primary endpoint
20 December 2022

20 December 2022

Quick facts

Lead sponsor	James J. Peters Veterans Affairs Medical Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	9 March 2020
Primary completion	20 December 2022
Estimated completion	20 December 2022
Sites	1 location across United States

Drugs / interventions tested

Combination of Neostigmine and Glycopyrrolate — full drug profile →
I-Box by Dynatronics

Conditions studied

Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
Constipation — all drugs for Constipation →
Fecal Incontinence — all drugs for Fecal Incontinence →
Neurogenic Bowel — all drugs for Neurogenic Bowel →

Sponsor

James J. Peters Veterans Affairs Medical Center

Who can join

Adults 18 to 70, any sex, with Spinal Cord Injuries or Constipation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in-vivo.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combining Therapeutic Strategies to Treat the Injured Spinal Cord: A Translational Perspective.
Sherman BC, Schmidt Read M, Hoh DJ, Guest JD, et al · · 2025 · cited 2× · PMID 40929022 · DOI 10.1177/08977151251371710
Recent Developments in On-Demand Voiding Therapies.
Thor KB, Marson L, Katofiasc MA, Ricca DJ, et al · · 2024 · cited 1× · PMID 38641354 · DOI 10.1124/jpet.123.002073

Verify or expand the search:

Other trials of Combination of Neostigmine and Glycopyrrolate

Trials testing the same drug.

NCT06351852 — Transdermal Administration by a Novel Wireless Iontophoresis Device · EARLY_PHASE1 · completed
NCT06351995 — Neostigmine and Glycopyrrolate by Iontophoresis · Phase 3 · active not recruiting

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting

Other James J. Peters Veterans Affairs Medical Center trials

Trials by the same sponsor.

NCT07251491 — Psilocybin to Treat Depression in Spinal Cord Injury · Phase 1, PHASE2 · not yet recruiting
NCT05960448 — Autonomic Effects of Spinal Cord Stimulation in Spinal Cord Injury · NA · recruiting
NCT05839652 — Treatment of Orthostatic Hypotension in SCI · Phase 4 · recruiting
NCT05422911 — Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. · Phase 2 · not yet recruiting
NCT06351852 — Transdermal Administration by a Novel Wireless Iontophoresis Device · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04027972 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by James J. Peters Veterans Affairs Medical Center
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04027972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing